Education
About Us
Working with TipRanks
Follow Us
KalVista Pharmaceuticals (KALV)
NASDAQ:KALV
KALV Stock Chart & Stats
$16.43
-$0.39(-4.51%)
At close: 4:00 PM EST
$16.43
-$0.39(-4.51%)
Day’s Range― - ―
52-Week Range$7.30 - $17.28
Previous CloseN/A
Volume49.40K
Average Volume (3M)1.49M
Market Cap
$830.48M
Enterprise ValueN/A
Total Cash (Recent Filing)$309.16M
Total Debt (Recent Filing)$149.59M
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Dec 04, 2025EPS Estimate
-1.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding50,546,290
10 Day Avg. Volume1,724,330
30 Day Avg. Volume1,491,066
Financial Highlights & Ratios
PEG Ratio-0.51
Price to Book (P/B)7.17
Price to Sales (P/S)0.00
P/FCF Ratio-4.47
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$31.14Price Target Upside89.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-3.27
Revenue Forecast (FY)$34.45M
Bulls Say, Bears Say
Bulls Say
Market DemandEkterly is on track to hit near peak prescriptions quickly, indicating robust market demand.
Market PenetrationKALV has already penetrated the market by approximately 10% in a few short months and will have the opportunity to entrench itself further prior to PHVS entry more than a year from now.
Sales PerformanceEkterly revenue hit $13.7mn in 3Q, significantly surpassing both FactSet consensus and analyst estimates.
Bears Say
Competitive PressureKALV shares reaction is muted which is attributed to the overhang of the imminent phase 3 trial readout of Pharvaris' deucrictibant.
Revenue VisibilityStock reaction was relatively muted as visibility into organic revenue remains limited due to no numerical detail on inventory contribution or payor KPIs.
Switching ConcernsThe key question is whether data here will be sufficient to drive meaningful switching from patients already prescribed Ekterly, as subtle differences in efficacy haven't really been the determinant of majority share.
KalVista Pharmaceuticals News
KALV FAQ
What was KalVista Pharmaceuticals’s price range in the past 12 months?
KalVista Pharmaceuticals lowest stock price was $7.30 and its highest was $17.28 in the past 12 months.
What is KalVista Pharmaceuticals’s market cap?
KalVista Pharmaceuticals’s market cap is $830.48M.
When is KalVista Pharmaceuticals’s upcoming earnings report date?
KalVista Pharmaceuticals’s upcoming earnings report date is Dec 04, 2025 which is 4 days ago.
How were KalVista Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is KalVista Pharmaceuticals overvalued?
According to Wall Street analysts KalVista Pharmaceuticals’s price is currently Undervalued.
Does KalVista Pharmaceuticals pay dividends?
KalVista Pharmaceuticals does not currently pay dividends.
What is KalVista Pharmaceuticals’s EPS estimate?
KalVista Pharmaceuticals’s EPS estimate is -1.05.
How many shares outstanding does KalVista Pharmaceuticals have?
KalVista Pharmaceuticals has 50,546,290 shares outstanding.
What happened to KalVista Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of KalVista Pharmaceuticals?
Currently, no hedge funds are holding shares in KALV
KalVista Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.14 (89.53% Upside)
$31.14 (89.53% Upside)
Blogger Sentiment
Bullish
KALV Sentiment 66%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 6.2%
Last 30 Days ▼ 7.5%
Last 30 Days ▼ 7.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
81.44%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
23.17%
Trailing 12-Months
Company Description
KalVista Pharmaceuticals
KalVista Pharmaceuticals (KALV) is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet needs. Operating primarily in the biotechnology sector, KalVista is dedicated to developing treatments for hereditary angioedema (HAE) and other plasma kallikrein-related diseases. The company's lead product candidate, sebetralstat, is being developed as a potential oral on-demand treatment for HAE attacks.
KALV Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive sentiment, highlighting significant achievements such as the FDA approval and successful early launch of EKTERLY, strong patient and prescriber engagement, and positive regulatory progress in Europe. However, challenges remain with high operating expenses and potential reimbursement hurdles with certain insurers.View all KALV earnings summariesKALV Stock 12 Month Forecast
Average Price Target
$31.14
▲(89.53% Upside)
Technical Analysis
Savara
―
Arvinas Holding Company
―
Gossamer Bio
―
Compass Therapeutics
―
Bicara Therapeutics Inc.
―
Ownership Overview
Currently, No data available
---